Physician profile
Patrick Ross Evans
NPI 1629547484
$4,805.30
in general payments reported to CMS, 2019-2025
26 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $736 · 2023: $907 · 2024: $804 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,818 · Education: $24.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,817.92 |
| Education | $24.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,035.50 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $452.27 | 2022-2025 | |
| Lilly USA, LLC | $378.73 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $365.23 | 2022-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $315.46 | 2022-2025 | Sotyktu |
| Journey Medical Corporation | $312.20 | 2022-2023 | |
| Genzyme Corporation | $257.91 | 2022-2025 | |
| Pfizer INC. | $220.45 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $215.18 | 2023-2025 | Zoryve |
| Ucb, INC. | $213.11 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $162.17 | 2021-2025 | |
| Botanix Sb INC | $148.70 | 2025 | Sofdra |
| Incyte Corporation | $132.62 | 2023-2025 | Opzelura |
| Amgen INC. | $124.48 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $68.09 | 2024-2025 | Aklief, Nemluvio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $64.24 | 2025 | Hadlima, Nexplanon, Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.23 | 2024-2025 | Siliq, Duobrii |
| Mayne Pharma Commercial LLC | $55.46 | 2025 | |
| Leo Pharma INC. | $52.55 | 2025 | Adbry |
| Verrica Pharmaceuticals INC. | $34.69 | 2023-2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.23 | 2025 | Spevigo |
| Dermavant Sciences, INC. | $28.08 | 2024 | Vtama |
| Janssen Biotech, INC. | $23.26 | 2025 | Tremfya |
| Corcept Therapeutics | $21.84 | 2024 | Korlym |
| Radius Health, INC. | $21.29 | 2024 | Tymlos |
| Exact Sciences Corporation | $13.33 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.